Published DateClear

Start Date

End Date

Category

• Pipeline3

Organizations

• Bausch + Lomb67
• Eyes On Eyecare53
• Alcon, Inc.47
• American Optometric Association38
• Harrow31
• Glaukos28
• Regeneron25
• Topcon Healthcare25
• Aldeyra Therapeutics21
• Sight Sciences19

Tags

• AMD2
• Geographic Atrophy2
• Cell Therapy1
• Clinical Trials1
• Cornea1
• Corneal Transplant1
• Retina1

• Organizations: Lineage Cell Therapeutics, Inc✕

Clear all

Pipeline

Lineage Cell Therapeutics launches new CED cell therapy program

Preclinical candidate COR1 is designed as an allogeneic source of corneal endothelial cells to replace damaged cells and restore corneal function.

Pipeline

OpRegen phase 1/2a trial data shows promise for GA

OpRegen RPE cell therapy is being developed and marketed through a global collaboration with Lineage Cell Therapeutics, Roche, and Regeneron.

Pipeline

Lineage launches phase 2a study by Genentech for GA secondary to AMD

With no current FDA-approved therapies for geographic atrophy secondary to AMD, RG6501 (OpRegen) could be a game-changer for patients.